Camosunate Tabs 7-13yrs

Camosunate Junior is an oral antimalarial medication containing two active ingredients in tablet form: Amodiaquine base (300 mg) and Artesunate (100 mg). It is an Artemisinin-based Combination Therapy (ACT) specifically designed for the treatment of uncomplicated malaria in older children and juniors aged 7–13 years.

As an ACT, it utilizes a dual-action mechanism: Artesunate provides rapid reduction of the parasite biomass in the blood, while Amodiaquine acts as a longer-acting agent to clear the remaining parasites. This combination therapy is essential for ensuring a high cure rate and helping to prevent the development of drug resistance in malaria parasites.

Key Benefits:

– Targeted Junior Formulation (Ages 7–13 Years)

– Effective Artemisinin-Based Combination (ACT)

– Rapid Symptom Relief and Parasite Clearance

– Dosage Optimized for Growing Children

CAUTION: This medication is a prescription-only treatment and must be administered according to a healthcare professional’s instructions. It is vital to complete the full 3-day course of treatment even if the child feels better earlier. Common side effects may include nausea, dizziness, or abdominal discomfort. Seek immediate medical attention if the child experiences severe vomiting, a skin rash, or if malaria symptoms persist.